Use of the Guardian™ Connect System With Smart Connected Devices

Type 1 Diabetes Mellitus Clinical Trial

Official title:

Use of the Guardian™ Connect System With Smart Connected Devices

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04809285
• Other study ID #: CIP331
• Status: Completed
• Phase: N/A
• Start date: April 6, 2021
• Est. completion date: September 29, 2023

Study information

• Verified date: March 2024
• Source: Medtronic Diabetes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin injection video capture and/or menstrual cycle tracking and/or cardiac monitoring in subjects with insulin requiring diabetes 2-80 years of age.

Description:

The study is a multi-center, prospective single-arm design without controls. All subjects will participate for a minimum of 90 days (Phase 1) and some subjects 18 years of age or older will participate for up to 9 months (Phase 2). All subjects will wear the Guardian Connect system (real-time continuous glucose monitoring (CGM)) continuously and use smart insulin pens or insulin pens with smart caps for multiple daily injections and continue their standard therapy throughout the duration of the study.

The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 217
• Est. completion date: September 29, 2023
• Est. primary completion date: September 29, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 80 Years

Eligibility

Inclusion Criteria

1. Individual is 2-80 years of age at time of consent.

2. A clinical diagnosis of type 1 or type 2 diabetes as determined by investigator for:

• at least the last 6 months for subjects 2-6 years of age

• at least the last 12 months for subjects 7-80 years of age

3. Subject is on multiple daily injection therapy (3 or more insulin injections per day one of which is a long acting insulin injection), is currently using or is willing and can afford to use insulin pen(s) and pen cartridge(s).

4. Subject is currently using or is willing to use the Guardian Connect system during the study.

5. Subject agrees to comply with the study protocol requirements.

6. For adult subjects: Subject is capable of providing legal consent without a legal authorized representative.

Exclusion Criteria

1. Subject is using a syringe and unwilling or unable to use insulin pen(s).

2. Subject is using an insulin pump.

3. Subject is currently using a non-Medtronic standalone CGM system and unwilling to use only the Guardian Connect system during the study.

4. Subject is using hydroxyurea at time of screening or plans to use it during the study.

5. Subject will not tolerate tape adhesive in the area of device placement as assessed by a qualified provider.

6. Subject has any unresolved adverse skin condition in the area of device placement (e.g. psoriasis, rash, Staphylococcus infection).

7. Subject is actively participating in or plans to enroll in an investigational study (e.g. drug or device), other than this study, wherein they have received treatment from an investigational drug or device.

8. Subject has a positive urine pregnancy test at time of screening.

9. Subject is female, sexually active without the use of contraception, able to become pregnant or plans to become pregnant during the course of the study.

10. Subject is unwilling to participate in study procedures.

11. Subject is directly involved in the study as research staff.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Device:
• Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management app
Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.

Locations

Country	Name	City	State
United States	Atlanta Diabetes Associates	Atlanta	Georgia
United States	Barbara Davis Center for Childhood Diabetes	Aurora	Colorado
United States	Texas Diabetes and Endocrinology	Austin	Texas
United States	AM Diabetes and Endocrinology Center	Bartlett	Tennessee
United States	Rocky Mountain Diabetes and Osteoporosis Center	Idaho Falls	Idaho
United States	Arkansas Diabetes and Endocrinology Center	Little Rock	Arkansas
United States	Loma Linda University Medical Center	Loma Linda	California
United States	Mary and Dick Allen Diabetes Center	Newport Beach	California
United States	Rhode Island Hospital (Lifespan Clinical Research Center)	Providence	Rhode Island
United States	Rainer Clinical Research Center	Renton	Washington
United States	Endocrine and Metabolic Consultants	Rockville	Maryland
United States	Endocrine Research Solutions, Inc.	Roswell	Georgia
United States	Texas Diabetes and Endocrinology	Round Rock	Texas
United States	Salinas Valley Memorial Healthcare System	Salinas	California

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Diabetes

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Time in Range	Percentage of Time in Range (SG <70 mg/dL, 70-180 mg/dL, and >180 mg/dL)	Up to 9 months